Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF Registry.
Administration, Oral
Adult
Aged
Aged, 80 and over
Anticoagulants
/ administration & dosage
Atrial Fibrillation
/ complications
Dose-Response Relationship, Drug
Factor Xa Inhibitors
/ administration & dosage
Female
Follow-Up Studies
Humans
Incidence
Japan
/ epidemiology
Male
Middle Aged
Registries
Retrospective Studies
Risk Factors
Stroke
/ epidemiology
Survival Rate
/ trends
Time Factors
Treatment Outcome
Warfarin
/ administration & dosage
Aged
Atrial fibrillation
Direct oral anticoagulant
Warfarin
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
05
03
2019
accepted:
31
05
2019
pubmed:
12
6
2019
medline:
25
2
2020
entrez:
12
6
2019
Statut:
ppublish
Résumé
Direct-acting oral anticoagulants (DOACs) are widely used in aged Japanese patients with atrial fibrillation (AF), but outcome data for such patients are limited. We compared outcomes between 1895 (58.5%) patients aged < 75 years (non-elderly), 1078 (33.3%) 75-84 years (elderly) and 264 (8.2%) ≥ 85 years (very elderly) enrolled in a prospective multicenter registry. Kaplan-Meier analysis (median follow-up: 39.3 months) revealed a significantly high incidence of stroke/systemic embolism (SE) among the very elderly relative to that among the non-elderly or elderly (3.2 vs. 1.2 and 1.5 events per 100 patient-years, p < 0.001). Major bleeding in the non-elderly group was significantly infrequent relative to that among the elderly or very elderly group (1.1 vs. 1.6 vs. 1.8 events, p = 0.033). After multivariate adjustment, the stroke/SE incidence was comparable between DOAC and warfarin users, regardless of age, but major bleeding decreased significantly among very elderly DOAC users (adjusted HR 0.220, 95% CI 0.042-0.920). The greater increasing incidence of stroke/SE than major bleeding as patients age suggests that stroke prevention should outweigh the bleeding risk when anticoagulants are being considered for aged patients. Our data indicated that DOACs can be a therapeutic option for stroke prevention in very elderly patients.
Identifiants
pubmed: 31183513
doi: 10.1007/s00380-019-01446-6
pii: 10.1007/s00380-019-01446-6
doi:
Substances chimiques
Anticoagulants
0
Factor Xa Inhibitors
0
Warfarin
5Q7ZVV76EI
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2021-2030Références
Circ J. 2016;80(4):843-51
pubmed: 27001190
Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1367-1377
pubmed: 28752560
J Am Heart Assoc. 2016 Feb 23;5(2):
pubmed: 26908412
Circ J. 2018 Sep 25;82(10):2500-2509
pubmed: 30078823
Thromb Haemost. 2009 Mar;101(3):422-7
pubmed: 19277401
Pharmacotherapy. 2017 Oct;37(10):1221-1230
pubmed: 28730619
J Arrhythm. 2017 Aug;33(4):289-296
pubmed: 28765759
J Cardiol. 2013 Apr;61(4):260-6
pubmed: 23403369
Circulation. 2011 May 31;123(21):2363-72
pubmed: 21576658
J Am Heart Assoc. 2017 Jul 23;6(7):null
pubmed: 28736385
Circulation. 2018 Jul 3;138(1):37-47
pubmed: 29490992
Circulation. 2014 Jul 8;130(2):138-46
pubmed: 24895454
Circ J. 2017 Aug 25;81(9):1278-1285
pubmed: 28428449
J Am Med Dir Assoc. 2015 May 1;16(5):358-64
pubmed: 25680239
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207971
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
Eur Heart J. 2014 Jul 21;35(28):1864-72
pubmed: 24561548
Circ J. 2013;77(3):632-8
pubmed: 23229461
Circ J. 2019 Mar 25;83(4):727-735
pubmed: 30726797
Thromb Haemost. 1993 Mar 1;69(3):236-9
pubmed: 8470047
JAMA Intern Med. 2016 Aug 1;176(8):1176-83
pubmed: 27379731
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Int J Cardiol. 2009 Oct 2;137(2):102-7
pubmed: 18691774
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Drugs Aging. 2010 Mar 1;27(3):239-54
pubmed: 20210369
Int Heart J. 2018 Nov 28;59(6):1266-1274
pubmed: 30369576